The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced ...

Li Qiang, director of the respiratory and critical care medicine department at the hospital, said the patient had over 10 ...

A "groundbreaking" cancer treatment trial by Memorial Sloan Kettering shows immunotherapy alone can eliminate some tumors, ...

Boehringer Ingelheim unveiled new data from its top oncology prospect zongertinib, further backing the drug’s prowess in ...

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced HER2-mutant non-small cell lung cancer – particularly those with specific HER2 ...

RxDx Device for non-small cell lung cancer has received Breakthrough Device Designation from the U.S. Food and Drug ...

Zongertinib, an oral therapy shown to have strong responses in patients previously treated for HER2 -mutated non–small cell ...

A new Stanford blood test detects cancer and tissue damage by analyzing rare RNA fragments in the blood. Stanford Medicine ...

With the American Association for Cancer Research’s annual conference now underway, oncology researchers can expect ...

According to the results of the early study, published simultaneously in the New England Journal of Medicine, 92% of patients ...

John Heymach, MD, PhD, The University of Texas MD Anderson Cancer Center, discusses the promising results of zongertinib for HER2-mutated non–small cell lung cancer, showcasing high response rates and ...

New research shows 92% of cancer patients stayed cancer-free for two years after immune-based therapy, potentially avoiding surgery and harsh treatments.